Pharmacologic therapy among patients with type 2 diabetes mellitus admitted to the cardiology service.
N Z Med J
; 136(1571): 30-40, 2023 Mar 10.
Article
em En
| MEDLINE
| ID: mdl-36893393
ABSTRACT
AIM:
To review the management of diabetes control in patients with type 2 diabetes admitted to the cardiology service at Auckland City Hospital for over 48 hours; to assess how many would potentially benefit from introduction of empagliflozin under current Pharmac guidelines.METHODS:
A retrospective audit of all admissions into cardiology between 1 November 2020 and 31 January 2021 prior to the availability of empagliflozin. Data collected included diagnosis and presence of type 2 diabetes, HbA1c and diabetes medications.RESULTS:
A total of 449 patients were admitted, of whom 98 had type 2 diabetes. The median age was 64 years old (IQR 56-76) and 66% of patients were male. Pacific peoples were over-represented in this study population. Fifty percent had an HbA1c>60mnmol/mol and diabetes medication was changed in 50% of these. Overall, 50% of patients would be eligible for empagliflozin under current criteria.CONCLUSIONS:
High proportions of patients have poor glycaemic control and are not up-titrated, suggesting a missed opportunity for medication optimisation. Pacific peoples are over-represented in this group, suggesting that they are at high risk of diabetes and cardiovascular admissions. Empagliflozin provides a targeted way to address renal and cardiovascular outcomes.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Cardiologia
/
Diabetes Mellitus Tipo 2
Tipo de estudo:
Guideline
/
Observational_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Oceania
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article